{name}
{subtitle}
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
city
~17 mi. (Gurgaon, India, +142 more cities)
facility
Fortis Memorial Research Institute
biomarker
del(11)(q10), +27 more biomarkers
drug
imetelstat, +1 more drug
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~37 mi. (New Delhi, India, +192 more cities)
facility
Maulana Azad Medical College
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
city
~37 mi. (New Delhi, India, +260 more cities)
facility
Max Super Speciality Hospital; Medical Oncology
biomarker
ERBB2 Amplification, +1 more biomarker
drug type
immunotherapy, +1 more type
To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.
city
~37 mi. (New Delhi, India)
facility
Institute of Liver & Biliary Sciences
drug
lenvatinib, +1 more drug
drug type
Other, +1 more type
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~40 mi. (Faridabad, India, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type